Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 28, 2023; 29(12): 1838-1851
Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1838
Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1838
Table 2 Cases of autoimmune hepatitis-like syndromes after coronavirus disease 2019 vaccine: Demographics, patient information, and disease presentation
| Classification | |
| Number of patients | 40 |
| Females, n (%) | 32 (83) |
| Age (years, mean ± SD) | 58.7 ± 16 |
| Race/ethnicity, n (%) | |
| Caucasian | 11 (27) |
| Asian | 3 (8) |
| Arabic | 1 (3) |
| Unspecified | 25 (62) |
| Predisposing conditions, n (%) | |
| History of liver disease | 6 (15) |
| History of autoimmune disease | 11 (28) |
| Medications, n (%) | |
| Acetaminophen | 3 (8) |
| Other hepatotoxic drugs (statins, peg-IFN, AZT) | 5 (13) |
| Vaccine, n (%) | |
| Pfizer-BioNTech | 17 (43) |
| Moderna | 11 (28) |
| AstraZeneca | 10 (25) |
| Coronavac | 2 (5) |
| Symptom onset (days after a dose, mean ± SD) | 16.6 ± 12.8 |
| Symptoms, n (%) | |
| Jaundice | 24 (60) |
| Astenia/Malaise/Fatigue | 13 (33) |
| Choluria | 10 (25) |
| Pruritus | 8 (20) |
| Abdominal pain | 4 (10) |
| Fever | 5 (13) |
| Loss of appetite | 4 (10) |
| Nausea/vomiting | 5 (13) |
- Citation: Sgamato C, Rocco A, Compare D, Minieri S, Marchitto SA, Maurea S, Nardone G. Autoimmune liver diseases and SARS-CoV-2. World J Gastroenterol 2023; 29(12): 1838-1851
- URL: https://www.wjgnet.com/1007-9327/full/v29/i12/1838.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i12.1838